Background: We aim to directly compare changes in lymphocyte subpopulations between chimeric (rituximab) and humanised (ocrelizumab) anti-CD20 antibodies in multiple sclerosis (MS).
Methods: In this retrospective analysis of prospectively collected data, we included 88 patients with MS, treated with rituximab (n=50) or ocrelizumab (n=38). We used flow cytometry in the peripheral blood to count total lymphocytes and lymphocytes expressing different phenotypic markers (CD4, CD8, CD19, CD20, CD4/CD8 ratio), before treatment and after 1, 3 and 6 months.
Results: On linear mixed effect regression models, after 1, 3 and 6 months, patients treated with rituximab and with ocrelizumab were similar in total lymphocyte count, CD19 lymphocytes, CD20 lymphocytes and CD4/CD8 ratio. However, patients treated with ocrelizumab presented with lower CD4 T lymphocytes and CD8 T lymphocytes after 1, 3 and 6 months (all p<0.05). No between-treatment difference in EDSS progression was found.
Discussion: B-cell levels in the peripheral blood were equally decreased by rituximab and ocrelizumab. On the contrary, CD4 and CD8 T lymphocyte reduction was more pronounced in ocrelizumab, when compared with rituximab, suggesting a broader immunomodulatory effect for the humanised antibody to be confirmed and correlated with clinical efficacy in the long term.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.msard.2021.102802 | DOI Listing |
Turk Neurosurg
May 2024
ankara universty.
Aim: Ischemic stroke remains one of the leading causes of death and disability worldwide and ca-rotid stenosis is the leading etiology of ischemic strokes of non-cardiac origin. The chronic inflammatory process and pro-inflammatory state in carotid stenosis seem to be the most im-portant underlying factor in carotid occlusion. In addition to medical therapy and carotid ar-tery stunting (CAS) in the treatment of carotid stenosis, carotid endarterectomy (CEA) is the main surgical treatment of carotid stenosis and its prognosis is the main subject of our study.
View Article and Find Full Text PDFTurk Neurosurg
February 2024
SBÜ Gaziosmanpaşa Eğitim ve Araştırma Hastanesi.
Aim: Minimally-invasive spinal surgery is increasingly being adopted worldwide. In this study, we evaluated the postoperative magnetic resonance imaging (MRI) findings and clinical outcomes of patients who underwent full endoscopic lumbar disk surgery.
Methods: Preoperative and postoperative 3rd and 6th month MRI features, visual analog scale (VAS) score, Oswestry Disability Index (ODI), and clinical features of patients who underwent percutaneous endoscopic lumbar discectomy between August 2009 and January 2012 were retrospectively analyzed.
J Endovasc Ther
January 2025
Department of Vascular Surgery, Northwest Hospital Group, Alkmaar, The Netherlands.
Objective: There is a lack of consensus regarding the optimal antithrombotic therapy (ATT) after popliteal and infrapopliteal (PIP) endovascular therapy (EVT). Currently, dual antiplatelet therapy (DAPT) for 3 months and single antiplatelet therapy (SAPT) are the most prescribed regimens in the Netherlands. Thus far, no randomized comparison has been performed on the optimal ATT approach.
View Article and Find Full Text PDFDiabetes Obes Metab
January 2025
Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK.
Aims: Evaluate glycated haemoglobin (HbA1c) and weight changes after 6 months of once-weekly (QW) injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in UK primary care.
Materials And Methods: Retrospective, non-interventional study, using the Clinical Practice Research Datalink Aurum primary care database, identified adults with type 2 diabetes (T2D) newly initiating a QW injectable GLP-1 RA between January 2020 and November 2021. Dual primary outcomes were proportion of patients with (1) HbA1c < 7% (<53 mmol/mol) and (2) weight loss categories (from 0% to 15+%) after 6 months of continuous GLP-1 RA therapy.
Sci Prog
January 2025
School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Purpose: The aim of this study was to evaluate the efficacy and safety of the Ahmed glaucoma valve in pediatric patients with refractory glaucoma.
Methods: A comprehensive literature search was conducted across multiple major databases, including PubMed, Embase, the Cochrane Library of Systematic Reviews, Science Direct, China's National Knowledge Infrastructure, and the Wanfang database. We retrieved studies published before December 2022 that met the inclusion criteria, including clinical controlled trials (randomized controlled trials) and clinical noncontrolled trials (non-randomized controlled trials) on the use of Ahmed glaucoma valve in pediatric patients with refractory glaucoma.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!